scholarly journals STUDY ON MIXING ANTI-A MONOCLONAL ANTIBODY AND ANTI-B MONOCLONAL ANTIBODY TO MAKE ANTI-AB SAVE AS ABO BLOOD GROUPING REAGENT

2018 ◽  
Vol 56 (1) ◽  
pp. 17
Author(s):  
Nguyen Thi Trung ◽  
Truong Nam Hai
Keyword(s):  
Monoclonal Antibody ◽  
Blood Group ◽  
Antibody Titer ◽  
Blood Group A ◽  
Group A ◽  
Group B ◽  
Abo Blood Grouping ◽  
Blood Grouping

So, it needs to balance the ratio of anti-A monoclonal antibody and anti-B monoclonal antibody  in the mixing so that the possibility of agglutination is the best. In this paper, anti-A monoclonal antibody (titer is 1/256) and anti-B monoclonal antibody (titer is 1/256) was used. The best results were obtained at one volume anti A monoclonal antibody is mixed one volume anti-B monoclonal antibody. The anti-A,B antibody titer was 1/128 for red blood group A and it was 1/128 for red blood group B. The intensity of agglutination reached  3+ for both red blood group A and B.

scholarly journals Relationship of ABO blood groups in patients with oral cancers

2016 ◽  
Vol 12 (1) ◽  
Author(s):  
Sajid Jamil ◽  
Naveed Akhtar Saleem ◽  
Syed Ikhlaq Amjad ◽  
Anjum Rashid Butt ◽  
Muhammad Tayyab ◽  
...  
Keyword(s):  
Blood Groups ◽  
Healthy Controls ◽  
Abo Blood Groups ◽  
Oral Cancers ◽  
Blood Group A ◽  
Group A ◽  
Group B ◽  
Relationship Of ◽  
Abo Blood Grouping ◽  
Blood Grouping

Present study was designed to find the association of ABO blood groups with oral cancers. In this study 50 diagnosed cases of oral cancers and 50 healthy controls were selected. ABO blood grouping, complete blood examination was performed in all these subjects. Out of 50 patients 16 were blood group A, 11 group `B`, 8 group `AB` and 15 belong to group `O` as compared to controls who were, 14, 15, 3, 18 for blood groups A, B, AB and O respectively. Conclusions: No relationship is found between Oral Cancers and ABO Blood groups.

scholarly journals ABO groups can play a role in susceptibility and severity of COVID-19

2021 ◽  
Vol 15 (1) ◽  
Author(s):  
S. Samra ◽  
M. Habeb ◽  
R. Nafae
Keyword(s):  
Blood Group ◽  
Abo Blood Group ◽  
Infection Group ◽  
Mechanically Ventilated ◽  
Blood Group A ◽  
Group A ◽  
Study Population ◽  
Group B ◽  
The Relationship ◽  
Seriously Ill

Abstract Background A few people infected by the coronavirus become seriously ill, while others show little to no signs of the symptoms, or are asymptomatic. Recent researches are pointing to the fact that the ABO blood group might play an important role in a person’s susceptibility and severity of COVID-19 infection. Aim of the study: try to understand the relationship between ABO groups and COVID-19 (susceptibility and severity). Results A total of (507) patients were included in this study. The study population was divided based on the ABO blood group into types A+, A−, B+, AB, O+, and O−. Blood group A was associated with high susceptibility of infection: group A, 381 (75.1%); and less common in group O, 97 (19.2%), group B, 18 (3.5%), and group AB, 11 (2.2%). The severity of COVID-19 infection was common in non-blood group O where (20 (7.1%), 4 (26.7%), 2 (11%), and 1 (9%) in type A+, A−, B+, and AB, respectively), while in type O 3.1%. And mechanically ventilated patients were 22 (5.9%), 2 (13.4%), 2 (11.1%), and 1 (1%). Mortality was high in blood groups A and B, 16 (4.37%) and 1 (5.5%), respectively, while in blood group O, it was 1%. Conclusion The incidence, severity, and mortality of COVID-19 were common in non-blood group O. While blood group O was protected against COVID-19.

scholarly journals Distribution of ABO and Rh blood groups in Nepalese medical students: a report

2000 ◽  
Vol 6 (1) ◽  
pp. 156-158
Author(s):  
T. Pramanik ◽  
S. Pramanik
Keyword(s):  
Medical Students ◽  
Blood Group ◽  
Blood Groups ◽  
Blood Group A ◽  
Group A ◽  
Group B ◽  
Group Distribution

The frequencies of ABO and rhesus blood groups vary from one population to another. We studied blood group distribution in 120 Nepalese students; 34% were blood group A, 29% group B, 4% group AB and 32.5% group O. The frequency of Rh-negative blood was 3.33% and Rh-positive 96.66%

scholarly journals DISTRIBUTION OF ABO AND RH (D) BLOOD GROUPS AMONG BLOOD DONORS IN DISTRICT MARDAN, PAKISTAN

1969 ◽  
Vol 3 (2) ◽  
pp. 318-322
Author(s):  
MUHAMMAD KHALID ◽  
NAILA ASLAM ◽  
MUHAMMAD SIYAR ◽  
RASHID AHMAD
Keyword(s):  
Blood Group ◽  
Blood Donors ◽  
Local Community ◽  
Healthy Adult ◽  
Blood Groups ◽  
Abo Blood Groups ◽  
Cross Sectional ◽  
Group B ◽  
Abo Blood Grouping ◽  
Blood Grouping

OBJECTIVE: To find out the distribution of ABO and Rh (D) blood groups among blood donors in districtMardan and to help transfusion services in the area.STUDY DESIGN: Cross sectional descriptive study.MATERIALS AND METHODS: The study was conducted in DHQ Hospital Mardan from 1st January2012 to 31st December 2012. A total of 2893 healthy adult, blood donors (both volunteer and directed) fromdistrict Mardan were included. Two ml of blood anti-coagulated with EDTA was taken and both ABO andRh (D) blood groups were determined using commercially available anti-sera of Biolaboratories. Thedistribution ofABO and Rh blood groups in the local community were then calculated.RESULTS: Among ABO blood groups “ B” (27.97%) was the most prevalent, followed by “0” (27.93%),“ A” (24.75%) and “ AB” (19.36%). Group Rh positive (94.30%) was more prevalent than Rh negative(5.70%). Similarly 0+ve (26.65%) was most frequent followed by B+ve (26.17%), A+ve (23.16%), AB+ve(18.32%), B've(1.80%),Ave(l.59%),O ve( 1.28%) and ABve( 1.04%).CONCLUSION: Blood group 'B' was most frequent among the ABO blood groups and Rh (D) positiveamong Rh blood groups while0+vewas the most frequent blood group in the study population.KEYWORDS: ABO Blood grouping, Rh (D) blood grouping, Mardan.

scholarly journals The association between blood groups and maxillofacial deformities

2008 ◽  
Vol 41 (02) ◽  
pp. 138-140
Author(s):  
Rasoul Gheisari ◽  
Mehdi Ghoreishian ◽  
Movahedian Bijan ◽  
Roozbehi Amrolah
Keyword(s):  
Blood Group ◽  
Blood Groups ◽  
Iranian Population ◽  
The Other ◽  
Chi Square ◽  
Genetic Characteristics ◽  
Blood Group A ◽  
Group A ◽  
Group B ◽  
Group Distribution

ABSTRACT Background: Blood group is a genetic characteristic which is associated with some diseases and deformities. Multifactorial characteristics of facial development make it difficult to predict a genetic pattern in a specific maxillofacial deformity, but epidemiological evaluations can reveal relationships between such deformities and some genetic characteristics or accompanied diseases, and this will help to recognise and treat them. The aim of this study is evaluation of the relationship between blood groups and maxillofacial deformities. Materials and Methods: In this study, blood groups of 190 patients with maxillofacial deformities who had had orthognathic surgery in Alzahra hospital, Isfahan, were compared with the general Iranian population. Results: Among 190 patients, 93 cases (49%) were men and 97 cases (51%) were women. Fifteen cases (8%) were < 20 years old, 130 cases (68%) were 20-30 years old, and the others (45 cases, 24%) were > 30 years old. The blood group distribution in our samples was as follows: blood group O = 76 cases (40%), blood group A = 58 cases (30%), blood group B = 41 cases (22%), and blood group AB = 15 cases (8%). Among these patients, 31 cases (16%) had maxillary deformities and 27 cases (14%) suffered from mandibular deformities while the other 132 cases (70%) had bimaxillary problems. The Chi-square test showed statistically significant differences between the blood group distribution of the patients of this study and the normal Iranian population ( P < 0.001). Conclusion: It was shown that among different blood groups; those with blood group B have a greater likelihood of association with maxillofacial deformities. On the other hand, the probability of the association of such deformities was the least with blood group A.

scholarly journals Some monoclonal antibody reagents (C219 and JSB-1) to P-glycoprotein contain antibodies to blood group A carbohydrate determinants: a problem of quality control for immunohistochemical analysis.

1991 ◽  
Vol 39 (12) ◽  
pp. 1603-1610 ◽  
Author(s):  
C L Finstad ◽  
B W Yin ◽  
C M Gordon ◽  
M G Federici ◽  
S Welt ◽  
...  
Keyword(s):  
Monoclonal Antibody ◽  
Blood Group ◽  
Immunohistochemical Analysis ◽  
Blood Type ◽  
Polymorphic Variation ◽  
Blood Group A ◽  
P Glycoprotein ◽  
Apparent Correlation ◽  
Group A ◽  
Type 3

Monoclonal antibodies (MAb) C219 and JSB-1 have been used extensively in the analysis of P-glycoprotein expression in normal and malignant tissues. This study demonstrates that some commercial lots of these MAb, even those supplied as purified immunoglobulins, contain contaminating anti-A blood group antibodies. In both sources of reagent, the antibody was specific for a particular A structure, known as repetitive or Type 3 A. These observations may account for earlier studies showing polymorphic variation in P-glycoprotein expression in epithelial tissues and an apparent correlation with the A blood type of the donor. Such reactivity can be eliminated by absorption of anti-P-glycoprotein reagents with A erythrocytes. These data re-emphasize the importance of evaluating MAb samples for unsuspected contaminating antibodies.

Prognostic value of the combination of blood group specificity and interleukin 28B gene polymorphism for estimation of efficiency of therapy with the use of pegylated interferon a-2 and ribavarin in patients with chronic genotype 1 hepatitis C

2016 ◽  
Vol 94 (3) ◽  
pp. 224-230
Author(s):  
P. P. Ogurtsov ◽  
Elena I. Kukhareva
Keyword(s):  
Hepatitis C ◽  
Gene Polymorphism ◽  
Blood Group ◽  
Hepatic Fibrosis ◽  
Pegylated Interferon ◽  
Interleukin 28B ◽  
Blood Group A ◽  
Group Specificity ◽  
Group A ◽  
Group B

Aim. To estimate the prognostic value of the combination of blood group specificity and interleukin 28B gene polymorphism for the achievement of sustained virologic response (SVR) to antiviral therapy (AVT) with the use ofpegylated interferon a-2 and ribavarin in patients with chronic genotype 1 hepatitis C (CHC-1). The secondary aim was to evaluate the influence of these genetic factors on the progress of hepatic fibrosis in case offailure of the above treatment. Materials and methods. A total of 146patients with CHC-1 were examined. We studied the RNA genotype of hepatitis C virus, blood group specificity, IL-28B gene polymorphism, and severity of hepatic fibrosis (puncture biopsies). Dynamics of hepatic fibrosis was followed up in 40 patients who failed to develop the virologic response. 20 control patients did not receive AVT. The multifactor significance criterion was used to identify the initial factor that produced the highest effect on SVR. Results. SVR was observed in 56.8% of the patients. Its efficiency was most significantly influenced by the combination of blood group specificity and interleukin 28B gene polymorphism (p=0.000024). Combination of blood group (0)1 with C/C or T/TIL-28B genotypes, A(II) with C/T or T/T, and B(III) with T/G was associated with SVR in 100, 88.2, and 94.4% cases respectively. It was absent in patients with blood group A(II) in combination with double-nucleotide substitution in rs8099917 of the IL-28B gene (TG and GG genotypes); these patients suffered progressive fibrosis. SVR occurred in 83.8% of the patients with blood group B(III). Conclusion. The knowledge of blood group in patients with CHC-1 and IL-28B gene polymorphism treated with the use of pegylated interferon a-2 and ribavarin allows to predict SVR with a probability of 100% in case of blood group 0(1) and C/C or T/T genotypes, 88.2% in case of blood group A(II) and single-nucleotide C>T substitution in rs8099917 locus of the IL-28B gene, 94.4% in case of blood group B(II) and single-nucleotide T>G substitution in the rs8099917 locus, 83.8% in case of blood group B(III). Treatment ofpatients with these genetic traits with antiviral drugs of direct action has no appreciable advances over treatment with AVT in combination with pegylated interferon a-2 and ribavarin (SVR above or around 85%). Patients with blood group A(II) and single- or double-nucleotide substitution in rs8099917 (TG or GG genotypes) have minimal chances to produce SVR to the above treatment. Simultaneous progression of hepatic fibrosis suggest that such therapy is undesirable in these cases. They should be regarded as main candidates for interferon-free therapy. Combination of blood group specificity and interleukin 28B gene polymorphism is a simple and reliable predictor of SVR and dynamics offibrosis in patients with CHC-1 receiving AVT with pegylated interferon a-2 and ribavirin; also, it may be an instrument of selection of patients for interferon-free therapy.

Sign in / Sign up

Export Citation Format

Share Document